Form 4: Zomedica Senior VP of Sales Granted 500,000 Stock Options

Russell Kevin Klass, Senior Vice President of Sales at Zomedica Corp., has been granted 500,000 options to purchase common stock with an exercise price of $0.05 per share.

Summary

• Russell Kevin Klass, the Senior Vice President of Sales for Zomedica Corp. (ZOMDF), reported the acquisition of 500,000 derivative securities.
• These derivative securities are options to buy common stock, granted with an exercise price of $0.05 per share.
• The options were granted on June 12, 2025, and have an expiration date of June 11, 2035.
• The vesting schedule for these options is structured such that one-quarter (1/4) vests on the first anniversary of the grant date (June 12, 2026).
• Following the initial vesting, 1/48 of the options will vest monthly thereafter until they are fully vested on June 11, 2029.
• Following this transaction, Mr. Klass beneficially owns 500,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It's a routine compensation event that aligns executive interests with shareholders, but it does not provide new information on company performance or strategic shifts.

Positives

• The grant of stock options to a senior executive like the Sr Vice President of Sales aligns their long-term interests with those of the shareholders, incentivizing performance and retention.
• The vesting schedule encourages long-term commitment from the executive, as full vesting occurs over several years.

Future Outlook

The document outlines the future vesting schedule for the granted stock options, with initial vesting on June 12, 2026, and full vesting by June 11, 2029. This indicates a long-term incentive structure for the executive.

Industry Context

The grant of stock options to senior executives is a common practice across various industries, particularly in the biotechnology and medical device sectors where long-term innovation and market penetration are key. This type of compensation aims to align executive performance with shareholder value creation over time.

Comparison to Industry Standards

• The structure of granting stock options with a multi-year vesting schedule is a standard practice in executive compensation across industries, including the animal health and diagnostics sector where Zomedica operates.
• The exercise price of $0.05 is notably low, which is common for options granted at or near the current market price of a penny stock, or as a deep in-the-money incentive.

Related Party Transactions

• The grant of 500,000 stock options to Russell Kevin Klass, a Senior Vice President of Sales, constitutes a related party transaction as it involves compensation from the company to an executive.

Stakeholder Impact

• Shareholders: The grant aims to align the executive's long-term interests with shareholder value creation, potentially leading to improved performance. However, future exercise of options could lead to dilution.
• Employees: This compensation structure may serve as a benchmark or incentive for other key employees.

Next Steps

• The options will begin to vest on June 12, 2026 (first anniversary of grant).
• Monthly vesting will continue until the options are fully vested on June 11, 2029.
• The options can be exercised at any time after vesting until their expiration on June 11, 2035.

Key Dates

Keywords

Zomedica Corp, ZOMDF, stock options, executive compensation, insider trading, Form 4, derivative securities, Russell Kevin Klass